ArticleNews reportPHN-05952026-11-02 02:00 CT
GLP-1 Focus or Broader Peptide Exposure: Which ETF Has the Edge?
Source · The Globe and Mail
TLDR
MarketBeat compared the GLP-1-focused Roundhill ETF (OZEM) with the broader REX Peptide ETF (PEPT), which it reports launched in October 2026. The article describes portfolios of 28 and 35 holdings, respectively, with substantial overlap despite different investment approaches.
01—Key points
- 01The article reports annual fees of 0.59% for actively managed OZEM and 0.65% for index-tracking PEPT.
- 02Eli Lilly and Novo Nordisk together account for more than a quarter of OZEM and approximately 23% of PEPT.
- 03The Globe and Mail labels the article third-party content that it has not reviewed; PEPT's short history limits performance comparisons.
Why it matters Editorial
The comparison highlights expanding investment exposure to peptide medicines while noting overlapping holdings, concentration risks and differing fees.
Summary generated with AI and reviewed by an editor. The original source governs; summaries can contain errors. Information only — not medical advice. Full disclaimer.
No related news yet.